Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Examining Ras/MAP Kinase Signaling in Primary Myelofibrosis May Yield Insight into the Mechanisms of JAK Inhibitor Resistance and Provide New Therapeutic Targets

Samuel B Reynolds, Malathi Kandarpa, Mark Ribick, Moshe Talpaz, Qing Li

Blood (2024) 144 (Supplement 1): 6568.

https://doi.org/10.1182/blood-2024-199399

Published: 2024

Journal Articles

Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2024-193193

Published: 2024

Journal Articles

PERK Maintains Hematopoietic Stem Cells Pool Integrity By Promoting Proliferation

Manxi Zheng, QinLu Peng, Erin M Kropp, Suxuan Liu, Zhengyou Yin, Zhejuan Shen, Sho Matono, Takao Iwawaki, Ken Inoki, Yang Mei, Qing Li, Lu Liu

Blood (2024) 144 (Supplement 1): 2656.

https://doi.org/10.1182/blood-2024-203086

Published: 2024

Journal Articles

Long-Term Efficacy Observation of Anti-BCMA CAR-T Cell Therapy Combined with Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma with Extramedullary Disease

QI Deng, Xin Li, Qing Li, Jia Wang, Juan Mu, Rui Cui

Blood (2024) 144 (Supplement 1): 4763.

https://doi.org/10.1182/blood-2024-205268

Published: 2024

Journal Articles

ERAD Activity Distinguishes the Functional Heterogeneity of Hematopoietic Stem Cells

QinLu Peng, Manxi Zheng, Suxuan Liu, Zhejuan Shen, Hanqi Liu, Xuezhen Ma, Zhengyou Yin, Yuhan Hu, Kaosheng Lv, Qing Li, Yang Mei, Lu Liu

Blood (2024) 144 (Supplement 1): 437.

https://doi.org/10.1182/blood-2024-203200

Published: 2024

Journal Articles

Inhibition of Endoplasmic Reticulum Associated Degradation Is Cytotoxic to Relapsed Refractory Multiple Myeloma through Altered Proapoptotic Signaling

Erin M Kropp, Sho Matono, Aaron Robida, Malathi Kandarpa, Olivia Wang, Andrew Alt, Moshe Talpaz, Matthew Pianko, Qing Li

Blood (2024) 144 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2024-203713

Published: 2024

Journal Articles

Relative Monocytosis Is Predictive of Disease Progression and Confirmatory of Response Assessment in Langerhans Cell Histiocytosis

Samuel B Reynolds, Sabrina Wilcox, Qing Li, Naina Chipalkatti, Asra Z. Ahmed

Blood (2023) 142 (Supplement 1): 5352.

https://doi.org/10.1182/blood-2023-190971

Published: 2023

Journal Articles

Comparison of Efficacy and Side Effects of BTK Inhibitors for Different Duration As a Bridging Therapy before Anti-CD19-CAR T-Cell Therapy in Patients with R/R DLBCL

QI Deng, Jia Wang, Rui Cui, Juan Mu, Xin Li, Qing Li, Lugui Qiu

Blood (2023) 142 (Supplement 1): 3482.

https://doi.org/10.1182/blood-2023-182855

Published: 2023

Journal Articles

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Blood (2023) 142 (Supplement 1): 628.

https://doi.org/10.1182/blood-2023-179141

Published: 2023

Journal Articles

Unrevealing Hematopoietic Reconstruction Discrepancies after Allo-UCBT and Allo-PBSCT at Single Cell Resolution

Qing Li, Linjie Wu, Fang Liu, Huimin Sun, Yingying Huo, Shihui Ma, Fang Dong, Xiaofan Zhu, Sha Hao, Tao Cheng

Blood (2023) 142 (Supplement 1): 1305.

https://doi.org/10.1182/blood-2023-187849

Published: 2023

Journal Articles

Identification of the Role of SEL1L in Platelet Function with Implications for Atypical Equine Thrombasthenia in Thoroughbred Horses

Anna R Dahlgren, Francesca Careddu, Raymond Adili, Erin Kropp, Qing Li, Michael Holinstat, Ida Biunno, Alessandra Balduini, Jordan Shavit, Fern Tablin, Carrie J Finno

Blood (2023) 142 (Supplement 1): 3944.

https://doi.org/10.1182/blood-2023-187146

Published: 2023

Journal Articles

Efficacy and Safety of Selinexor-Based Combination Therapy in CNS Lymphoma: A Retrospective Experience

Li Li, Yan Ma, Xiaobo Wang, Zhiming Li, Zhiguang Lin, Qi Zhang, Jay Mei, Jingjing Ma, Xin Gao, Hui Kang, Zhijia Zhao, Hang Yang, Qing Li, Mengxue Zhang, Yingbo Zhou, Bobin Chen

Blood (2023) 142 (Supplement 1): 6301.

https://doi.org/10.1182/blood-2023-184682

Published: 2023

Journal Articles

Ras Activity Is Significantly Elevated in Patients with Primary Myelofibrosis and Is Agnostic to the Presence of RAS and JAK pathwaymutations

Samuel B Reynolds, Malathi Kandarpa, Kristen Marie Pettit, Mark Ribick, Moshe Talpaz, Qing Li

Blood (2023) 142 (Supplement 1): 6347.

https://doi.org/10.1182/blood-2023-179503

Published: 2023

Journal Articles

Chidamide Combined with Cytarabine Plays a Role in the Treatment of AML By Down-Regulating the MYC-RRP9 Pathway

Qing Li, Yu Wu

Blood (2022) 140 (Supplement 1): 11772–11773.

https://doi.org/10.1182/blood-2022-164588

Published: 2022

Journal Articles

Prevalence, Severity, Trajectory, and Predictors of Symptom Burdens Among Adolescents and Young Adults with Hodgkin Lymphoma: A Population-Based Cohort Study

Sumit Gupta, Qing Li, Paul Nathan, Norma D'Agostino, Nancy N Baxter, Colleen Fox, Natalie Coburn, Rinku Sutradhar

Blood (2022) 140 (Supplement 1): 5162–5163.

https://doi.org/10.1182/blood-2022-160098

Published: 2022

Journal Articles

Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Vikas Gupta, Francesca Palandri, Timothy Devos, Raajit K Rampal, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Qing Li, Sandra Klein, Claire Harrison

Blood (2022) 140 (Supplement 1): 586–589.

https://doi.org/10.1182/blood-2022-158147

Published: 2022

Journal Articles

CD117 Antibody Drug Conjugate-Based Conditioning Allows for Efficient Engraftment of Gene-Modified CD34+ Cells in a Rhesus Gene Therapy Model

Naoya Uchida, Ulana Stasula, Malikiya Hinds, Paula Germino-Watnick, Allen E. Krouse, N Seth Linde, Aylin C. Bonifacino, Kellie Latimer, Prashant Bhattarai, Nicholas C. Yoder, Rahul Palchaudhuri, Qing Li, Kirk Bertelsen, Lisa Olson, Robert E. Donahue, John F. Tisdale

Blood (2021) 138 (Supplement 1): 560.

https://doi.org/10.1182/blood-2021-145524

Published: 2021

Journal Articles

The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes

Eugene Brailovski, Qing Li, Ning Liu, Brian Leber, Dina Khalaf, Mitchell Sabloff, Grace Christou, Karen Yee, Lisa Chodirker, Anne Parmentier, Mohammed Siddiqui, Alexandre Mamedov, Liying Zhang, Ying Liu, Craig C. Earle, Matthew Cheung, Nicole Mittman, Rena J. Buckstein, Lee Mozessohn

Blood (2021) 138 (Supplement 1): 3064.

https://doi.org/10.1182/blood-2021-149855

Published: 2021

Journal Articles

Blinatumomab Is Cost-Effective Compared to Standard Chemotherapy for Children with High Risk Relapses of Acute Lymphoblastic Leukemia: A Cost-Effectiveness Analysis Using Population-Based Healthcare Data

Petros Pechlivanoglou, Linda Luu, Qing Li, Paul J. Gibson, Uma H. Athale, Mylene Bassal, Vicky R. Breakey, Serina Patel, Jason Pole, Rinku Sutradhar, Laura Wheaton, Nicole Mittmann, Sumit Gupta

Blood (2021) 138 (Supplement 1): 565.

https://doi.org/10.1182/blood-2021-154193

Published: 2021

Journal Articles

Rates and Predictors of Visits to Primary Care Physicians during and after Treatment of Childhood Acute Lymphoblastic Leukemia: A Population-Based Cohort Study

Vicky R. Breakey, Paul Nathan, Serina Patel, Laura Wheaton, Qing Li, Rinku Sutradhar, Mylene Bassal, Paul J. Gibson, Jason Pole, Uma H. Athale, Sumit Gupta

Blood (2021) 138 (Supplement 1): 839.

https://doi.org/10.1182/blood-2021-147326

Published: 2021

NARROW

Examining Ras/MAP Kinase Signaling in Primary Myelofibrosis May Yield Insight into the Mechanisms of JAK Inhibitor Resistance and Provide New Therapeutic Targets

Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis

PERK Maintains Hematopoietic Stem Cells Pool Integrity By Promoting Proliferation

Long-Term Efficacy Observation of Anti-BCMA CAR-T Cell Therapy Combined with Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma with Extramedullary Disease

ERAD Activity Distinguishes the Functional Heterogeneity of Hematopoietic Stem Cells

Inhibition of Endoplasmic Reticulum Associated Degradation Is Cytotoxic to Relapsed Refractory Multiple Myeloma through Altered Proapoptotic Signaling

Relative Monocytosis Is Predictive of Disease Progression and Confirmatory of Response Assessment in Langerhans Cell Histiocytosis

Comparison of Efficacy and Side Effects of BTK Inhibitors for Different Duration As a Bridging Therapy before Anti-CD19-CAR T-Cell Therapy in Patients with R/R DLBCL

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Unrevealing Hematopoietic Reconstruction Discrepancies after Allo-UCBT and Allo-PBSCT at Single Cell Resolution

Identification of the Role of SEL1L in Platelet Function with Implications for Atypical Equine Thrombasthenia in Thoroughbred Horses

Efficacy and Safety of Selinexor-Based Combination Therapy in CNS Lymphoma: A Retrospective Experience

Ras Activity Is Significantly Elevated in Patients with Primary Myelofibrosis and Is Agnostic to the Presence of RAS and JAK pathwaymutations

Chidamide Combined with Cytarabine Plays a Role in the Treatment of AML By Down-Regulating the MYC-RRP9 Pathway

Prevalence, Severity, Trajectory, and Predictors of Symptom Burdens Among Adolescents and Young Adults with Hodgkin Lymphoma: A Population-Based Cohort Study

Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

CD117 Antibody Drug Conjugate-Based Conditioning Allows for Efficient Engraftment of Gene-Modified CD34+ Cells in a Rhesus Gene Therapy Model

The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes

Blinatumomab Is Cost-Effective Compared to Standard Chemotherapy for Children with High Risk Relapses of Acute Lymphoblastic Leukemia: A Cost-Effectiveness Analysis Using Population-Based Healthcare Data

Rates and Predictors of Visits to Primary Care Physicians during and after Treatment of Childhood Acute Lymphoblastic Leukemia: A Population-Based Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only